Effect of switching from glatiramer acetate 20  mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study

Glatiramer acetate (GA) 40  mg × 3/weekly was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While the beneficial effect of GA 20 mg/daily in MS patients on non-conventional MRI measures has been demonstrated, the effect of GA 40 mg × 3/weekly at the microstructural tissue level h as yet to be explored.

Source: Journal of the Neurological Sciences - February 10, 2018 Category: Neurology Authors: Robert Zivadinov, Niels Bergsland, Jesper Hagemeier, Eleonora Tavazzi, Deepa P. Ramasamay, Jackie Durfee, Mariya Cherneva, Ellen Carl, Jillian Carl, Channa Kolb, David Hojnacki, Bianca Weinstock-Guttman Source Type: research